AMENDMENTS TO THE CLAIMS

1.   (Original)   An isolated nucleic acid molecule comprising a sequence selected from the group consisting of:

(a)   a sequence provided in SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 and 25;

(b)   a complement of a sequence provided in SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 and 25;

(c)   a sequence consisting of at least 10 contiguous nucleotides of a sequence provded in SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 and 25 or a complementary form thereof;

(d)   a sequence which hybridizes to the complement of a sequence provided in SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 and 25, under conditions of low stringency;

(e)   a sequence having at least 70% identify after optimal alignment to a sequence provided in SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 and 25;

(f)   a derivative of a sequence provided in SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 and 25; and

(g)   a homolog of a sequence provided in SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 and 25.

2.   (Original)   A vector comprising a nucleic acid molecule of Claim 1 operably linked to an expression control sequence.

3.   (Original)   The vector of Claim 2, wherein the vector is an artificial chromosome.

4.   (Original)   The vector of Claim 3, wherein the vector is an artificial human chromosome.

5.   (Previously presented)   A host cell transformed or transfected with the vector of Claim 2.

6.   (Original)   An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

(a)   a sequence provided in SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 27 and 28;

(b)   a sequence having at least 70% similarity after optimal alignment to an amino acid sequence provided in SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 27 and 28;

(c)   a derivative, homolog, analog, chemical equivalent or mimetic of a sequence provided in SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 27 and 28;

(d)   a sequence encoded by a nucleic acid molecule of Claim 1; and

(e)   a sequence having at least 70% similarity after optimal alignment to a sequence encoded by a nucleic acid molecule of Claim 1.

7.   (Original)   A vector comprising a nucleic acid molecule which encodes a polypeptide of Claim 6 operably linked to an expression control sequence.

8.   (Original)   The vector of Claim 7, wherein the vector is an artificial chromosome.

9.   (Original)   The vector of Claim 8, wherein the vector is a human artificial chromosome.

10.   (Previously presented)   A host cell transformed or transfected with the vector of Claim 7.

11.   (Original)   An isolated immunointeractive molecule which specifically binds to a polypeptide of Claim 6 or an immunogenic fragment thereof.

12.   (Original)   The immunointeractive molecule of Claim 11, wherein the molecule is an antibody or an antigen binding fragment thereof.

13.   (Previously presented)   The isolated antibody of Claim 12, wherein said antibody is selected from the group consisting of: a polyclonal antibody, a monoclonal antibody, a humanized antibody, and a deimmunized antibody.

14.   (Previously presented)   The antibody of Claim 12 conjugated to an immunotoxin.

15.   (Previously presented)   A composition comprising a first component and a second component selected from a pharmaceutical carrier, diluent and an immunostimulant.

16.   (Previously presented)   A method for detecting the presence of a disease or condition in a subject, comprising the steps of:

(a)   obtaining a biological sample from said subject;

(b)   contacting said biological sample with an molecule that binds to a polypeptide Claim 6;

(c)   detecting in said biological sample the presence of binding of said molecule; and

(d)   comparing the presence of bound molecule with a pre-determined cut-off value to make a determination as to the presence or absence of a disease or condition in said subject.

17.   (Original)   The method of Claim 16, wherein said disease or condition is AML.

18.   (Original)   The method of Claim 16, wherein said molecule is an antibody.

19-26.   (Canceled)

27.   (Previously presented)   A composition comprising a first component comprising a polypeptide of Claim 6 and a second component selected from the group consisting of: a pharmaceutical carrier, diluent and an immunostimulant.

28.   (Previously presented)   A composition comprising a first component comprising an immunointeractive molecule of Claim 11 and a second component selected from the group consisting of: a pharmaceutical carrier, diluent and an immunostimulant.

29.   (Previously presented)   A method for detecting the presence of a disease or condition in a subject, comprising the steps of:

(a)   obtaining a biological sample from said subject;

(b)   contacting said biological sample with an molecule that binds to a nucleic acid molecule of Claim 1;

(c)   detecting in said biological sample the presence of binding of said molecule; and

(d)   comparing the presence of bound molecule with a pre-determined cut-off value to make a determination as to the presence or absence of a disease or condition in said subject.